11OXO, Essential Adrenals Collection
11OXO, Essential Adrenals Collection
11OXO, Essential Adrenals Collection

11OXO, Essential Adrenals Collection

Regular price
Sold out
Sale price
$45.99
Shipping calculated at checkout.

Prototype Nutrition's 11OXO contains a fast-acting formula of Adrenosterone, a natural hormone produced in the adrenal gland that modifies the activity of cortisol in the body. Adrenosterone, and its metabolite11-ketotestosterone, and reduce cortisol levels in target tissues via inhibition of 11beta-hydroxysteroid dehydrogenase type I (11b-HSDI), converting circulating inactive cortisone into active cortisol.

This product contains 50mg of active per dose. Recommended stack with 11 Spray.

This product is great for use in enhanced energy, libido, and lean body mass. Expected results are:

  • Rapid reduction in waist/stomach size, reduced visceral fat
  • Increased strength, greater muscle blood flow and pump
  • Increased glucose disposal in muscle
  • Body re-compositioning
  • Targeted cortisol control
  • Reduced liver production of glucose

About Prototype Nutrition's Essential Adrenals Collection

Natural steroid hormones, whether they be estrogens, progesterone, testosterone, cortisol, DHEA etc. are often given to individuals in various forms to correct deficiencies in natural production. However, these natural bioidentical hormones are often poorly bioavailable when taken orally, given the fact that they must pass through the liver before entering the general circulation. This “first pass” liver phenomenon typically results in the vast majority of the hormone being metabolized into inactive compounds, with very little active hormone reaching the rest of the body.

Many methods have been tried to overcome this problem. Some have developed synthetic analogs of the hormones that resist first pass liver degradation. However, these don’t always share the full benefits of the natural hormone and could be somewhat toxic. Other solutions, such as transdermal creams, gels, or sprays have been utilized as well as popularized here on the PN line as another effective method of administration. Injections as well are quite effective, but of course are inconvenient and uncomfortable. This sublingual technology is great for those who wish to stack multiple PN products without having to worry about body “real estate” or for those who find the sprays drying during the winter months. Additionally, sublingual administration makes the Essential Adrenals method fast acting in comparison to topically boosting blood circulation or relying on other oral ingestion methods.

Cyclodextrin Technology

Cyclodextrins are sugar derivatives whose molecules have hollow non-polar (fat like) interiors and polar (water like) exteriors.  Steroid hormones, such as DHEA and Beta AET, can incorporate into the fatty interior of the cyclodextrin forming a cyclodextrin complex, which is then able to dissolve easily in water. This water solubility then allows the steroid hormone to pass through the lining of the mouth with great ease, as the steroid simply releases from the cyclodextrin and into the lipophilic and heavily vascularized lining of the mouth (specifically under the tongue).  Since substances entering the body through the mouth lining do not have to “pass through” the liver right away (like with oral consumption), a great increase in bioavailability is achieved. *

Hydroxypropyl-beta-cyclodextrin is the preferred form of cyclodextrin for steroid inclusion complexes. This is what is used in Prototype’s Essential Adrenal Series.

* One of the first published papers establishing the efficacy of HPCD / steroid complexes on bioavailability was published in 1986. You may read more here: https://www.ncbi.nlm.nih.gov/pubmed/3958926

Due to the sensitive and highly limited resources and products used in the Prototype line, for customer safety, we do not accept returns as returned items cannot be restocked. Please carefully consider this before your purchase.

 **References:

Antiglucocorticoid function of androstenetriol

Psychoneuroendocrinology, Volume 22, Supplement 1, 1997, Pages S103-S108

Roger M. Loria

Immune up-regulation and tumor apoptosis by androstene steroids

Steroids, Volume 67, Issue 12, November 2002, Pages 953-966

Roger M. Loria

Androstenetriol improves survival in a trauma-hemorrhage shock model

Brain, Behavior, and Immunity, Volume 19, Issue 4, Supplement 1, July 2005, Page e46

Roger M. Loria, Andreea C. Marcu, Hans W. Carter, Wayne R. Barbee, Rao R. Ivatury, Kevin R. Ward

Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice

International Journal of Immunopharmacology, Volume 22, Issue 1, 1 January 2000, Pages 1-14

Mark H. Whitnall, Thomas B. Elliott, Rita A. Harding, Cynthia E. Inal, Michael R. Landauer, Catherine L. Wilhelmsen, LuAnn McKinney, Venita L. Miner, William E. Jackson III, Roger M. Loria, G. David Ledney, Thomas M. Seed

Androstenetriol and androstenediol. Protection against lethal radiation and restoration of immunity after radiation injury.

Loria RM, Conrad DH, Huff T, Carter H, Ben-Nathan D.

Ann N Y Acad Sci. 2000;917:860-7.

Control of the immune response by DHEA and its metabolites.

Loria RM, Padgett DA.

Rinsho Byori. 1998 Jun;46(6):505-17.

In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenetriol.

Padgett DA, Loria RM.

J Immunol. 1994 Aug 15;153(4):1544-52.

Beta-Androstenes and Resistance to Viral and Bacterial Infections

Roger M. Loria

Neuroimmunomodulation 2009;16:88-95 (DOI: 10.1159/000180263)

The Immunobiology and Therapeutic Potential of Androstene Hormones and Their Synthetic Derivatives: Novel Anti-Inflammatory and Immune Regulating Steroid Hormones

Mod. Asp. Immunobiology. 3(2), 64-70, 2003

Dominick L. Auci, Clarence Ahlem, Mei Li, Richard Trauger, Charles Dowding, Florence Paillard, James Frincke and Christopher L. Reading

7-Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases

Dominick L. Auci, Christopher L. Reading and James M. Frincke

Autoimmunity Reviews, Volume 8, Issue 5, March 2009, Pages 369-372